Long Non-Coding RNAs (lncRNAs) in Heart Failure: A Comprehensive Review

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Heart failure (HF) is a widespread cardiovascular condition that poses significant risks to a wide spectrum of age groups and leads to terminal illness. Although our understanding of the underlying mechanisms of HF has improved, the available treatments still remain inadequate. Recently, long non-coding RNAs (lncRNAs) have emerged as crucial players in cardiac function, showing possibilities as potential targets for HF therapy. These versatile molecules interact with chromatin, proteins, RNA, and DNA, influencing gene regulation. Notable lncRNAs like Fendrr, Trpm3, and Scarb2 have demonstrated therapeutic potential in HF cases. Additionally, utilizing lncRNAs to forecast survival rates in HF patients and distinguish various cardiac remodeling conditions holds great promise, offering significant benefits in managing cardiovascular disease and addressing its far-reaching societal and economic impacts. This underscores the pivotal role of lncRNAs in the context of HF research and treatment.

Cite

CITATION STYLE

APA

Jha, S., Thasma Loganathbabu, V. K., Kumaran, K., Krishnasamy, G., & Aruljothi, K. N. (2024, February 1). Long Non-Coding RNAs (lncRNAs) in Heart Failure: A Comprehensive Review. Non-Coding RNA. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ncrna10010003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free